FOR IMMEDIATE RELEASE

CONTACT:

Investor Relations	Carl Hymans
Tiens Biotech Group (USA), Inc.	G. S. Schwartz & Co.
Tel: +86-22-8213-7594	Tel: 212-725-4500
Fax: +86-22-8213-7594	Fax: 212-725-9188
Email: investor@tiens-bio.com	Email: carlh@schwartz.com
http://www.tiens-bio.com

TIENS BIOTECH GROUP (USA) REPORTS SECOND QUARTER AND SIX-MONTH RESULTS

NEW YORK – August 19, 2010 –Tiens Biotech Group (USA), Inc. (the “Company” or “Tiens”, NYSE AMEX: TBV), www.tiens-bio.com, today announced financial results for the second quarter and six months ended June 30, 2010.

Revenue for the second quarter of 2010 was $8.2 million, compared to $20.6 million for the second quarter of 2009. Revenue for the six months ended June 30, 2010 was $19.6 million, compared to $38.8 million for the first six months of 2009.

Net income for the second quarter of 2010 was $0.5 million, or $0.01 per share, compared to net income of $10.3 million, or $0.14 per share, for the 2009 second quarter. For the six months ended June 30, 2010, net income was $4.1 million, or $0.5 per share, compared to $19.3 million, or $0.26 per share for the first six months of 2009.

The decrease in revenue was mainly due to a decrease in international sales which reflects China’s Administration of Quality Supervision, Inspection and Quarantine carrying out a national campaign against unsafe food and substandard products in 2008, which brought on a general slow-down and backlog of export clearances for Chinese food products. Upon the lifting of the regulations, overseas affiliated companies began to purchase more products, thereby increasing sales in the first two quarters of 2009. Second quarter 2010 sales to Indonesia, Russia, Vietnam and Peru further decreased due to the distributors in these countries purchasing more products in the first half of 2009, after the 2008 product scarcity. The decrease in sales in China was mainly due to domestic distributors’ reduced purchasing demand following their stocking up of products during 2009. Management believes the decrease in revenues is temporary, and that revenue growth will resume in the near future.

Other Highlights

Cost of sales for the second quarter of 2010 decreased to $3.0 million, or 50.3%, compared to $6.1 million for the same period in 2009. For the six months ended June 30, 2010, cost of sales was $6.5 million, a decrease of 45.3% compared to $11.9 million for the same period in 2009. Cost of sales for the period decreased at a slightly lower rate than revenue, primarily due to fixed costs, which do not increase or decrease in line with revenue changes.

Gross profit for the second quarter of 2010 was $5.1 million, a decrease of 64.5% compared to $14.4 million for the same period in 2009. The gross profit margin for the second quarter of 2010 was 62.8%, compared to 70.2% for the same period in 2009. For the six months ended June 30, 2010, gross profit was $13.1 million, a decrease of 51.4% compared to the same period in 2010, and the gross profit margin was 66.9% compared to 69.4% for the same period in 2009. These decreases were mainly due to the decrease of revenue overall and fixed costs, which do not increase or decrease in line with revenue changes.

Selling, general and administrative expenses were $4.1 million for the second quarter of 2010, an increase of 1.4% compared to $4.0 million for the same period in 2009. This increase was primarily due to the increase in research and development expenses. Selling, general and administrative expenses as a percentage of sales were 49.8% for the second quarter of 2010 compared to 19.5% for the same period in 2009. For the six months ended June 30, 2010, selling, general and administrative expenses were $7.6 million, an increase of 5.9% compared to $7.1 million in the same period in 2009. This increase was mainly due to the increase in research and development expense. For the six months ended June 30, 2010, selling, general and administrative expenses as a percentage of sales was 38.7%, compared to 18.4% for the same period in 2009.

As of June 30, 2010, Tiens had $126.8 million of retained earnings and total shareholders' equity of $180.4 million.

Jinyuan Li, Chairman, President and CEO of Tiens, said, “We believe that our international and domestic sales will return to and possibly exceed previous levels as our domestic and overseas affiliated companies have indicated that they are not seeing sizable declines of their revenue, and that they expect that the market fluctuation will be temporary. They believe that revenue growth will resume in the near future, consistent with what they have achieved during the majority of the past 15 years. We remain committed to building greater market share in China, expanding our international customer base, and remaining focused on our efforts to generate long-term domestic and international growth.”

About Tiens Biotech Group (USA), Inc. www.tiens-bio.com

Tiens Biotech Group (USA), Inc. (NYSE AMEX: TBV) conducts its business operations from Tianjin, People’s Republic of China. Tiens primarily engages in the research, development, manufacturing, and marketing of nutrition supplement products, including wellness products and dietary supplements.

Tiens derives its revenues principally from product sales to affiliated companies in China and internationally in 54 countries. Since its establishment, Tiens has developed and produced 37 nutrition supplements, which include wellness products and dietary supplements. Tiens develops its products at its own product research and development center, which employs highly qualified professionals in the fields of pharmacology, biology, chemistry and fine chemistry. Tiens has obtained all required certificates and approvals from government regulatory agencies to manufacture and sell its products in China.

In China, Tiens conducts the marketing and sales of its products through its affiliated company, Tianshi Engineering. Tianshi Engineering markets and sells Tiens’ products in China through chain stores, domestic affiliated companies, and its 92 branches. Outside of China, Tiens sells its products to affiliated companies in 54 countries who in turn sell through an extensive direct sales force, or multi-level marketing sales force. The Company’s direct sales marketing program is subject to governmental regulation in each of these countries.

Certain statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Such forward-looking statements are not necessarily indicative of future financial results, and may involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to: (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; whether Tianshi Engineering, the Company’s affiliate which sells its products in China, obtains a direct selling license in China; and (v) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at http://www.sec.gov under "Search for Company Filings."

-Tables Follow-

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2010 and 2009 (UNAUDITED)

	Three months ended June 30,						Six months ended June 30,
	2010			2009			2010			2009
REVENUE - RELATED PARTIES	$	8,167,849		$	20,551,036		$	19,571,212		$	38,788,581

COST OF SALES - RELATED PARTIES		3,037,847			6,117,409			6,478,728			11,852,468

GROSS PROFIT		5,130,002			14,433,627			13,092,484			26,936,113

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES		4,069,097			4,014,591			7,566,644			7,145,527

INCOME FROM OPERATIONS		1,060,905			10,419,036			5,525,840			19,790,586

(Interest expense)		-			(53,201	)		-			(105,817	)
Interest income		3,846			100,779			5,718			186,547
Other expense		(418,260	)		(28,144	)		(671,970	)		(73,432	)
OTHER (EXPENSE) INCOME, NET		(414,414	)		19,434			(666,252	)		7,298

INCOME BEFORE INCOME TAXES		646,491			10,438,470			4,859,588			19,797,884

INCOME TAXES		138,621			123,101			748,123			482,716

NET INCOME	$	507,870			10,315,369			4,111,465			19,315,168

LESS: Net income attributable to the noncontrolling interest		(122,083	)		(139,071	)		(464,140	)		(546,045	)

NET INCOME ATTRIBUTABLE TO THE COMPANY		385,787			10,176,298			3,647,325			18,769,123

OTHER COMPREHENSIVE INCOME:
Foreign currency translation adjustment		766,901			151,289			1,125,269			770,887

COMPREHENSIVE INCOME		1,152,688			10,327,587			4,772,594			19,540,010

COMPREHENSIVE INCOME ATTRIBUTABLE
TO THE NONCONTROLLING INTEREST		163,465			140,300			506,863			559,895

COMPREHENSIVE INCOME ATTRIBUTABLE
TO THE COMPANY	$	989,223		$	10,187,287		$	4,265,731		$	18,980,115

EARNINGS PER SHARE,
BASIC AND DILUTED	$	0.01		$	0.14		$	0.05		$	0.26

WEIGHTED AVERAGE NUMBER OF SHARES,
BASIC AND DILUTED		71,333,586			71,333,586			71,333,586			71,333,586

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

AS OF JUNE 30, 2010 (UNAUDITED) AND DECEMBER 31, 2009

	June 30,		December 31,
	2010		2009
	(Unaudited)
ASSETS

CURRENT ASSETS:
Cash	$	5,660,772	$	1,848,328
Accounts receivable, trade - related parties, net of
allowance for doubtful accounts of $1,307,687 and $1,419,178
as of June 30, 2010 and December 31, 2009, respectively		8,809,737		15,379,312
Inventories		5,776,964		5,328,052
Other receivables		2,354,237		995,657
Other receivables - related parties		33,035,274		44,561,626
Employee advances		238,075		115,673
Prepaid expenses		351,905		658,193
Prepaid taxes		121,542		407,534
Total current assets		56,348,506		69,294,375

PROPERTY, PLANT AND EQUIPMENT, net		9,946,030		10,124,483

OTHER ASSETS:
Construction in progress		146,343,059		125,572,621
Construction deposits		5,068,290		1,405,997
Intangible assets, net		12,764,848		12,864,295
Other assets		18,039,203		11,847,937
Total other assets		182,215,400		151,690,850

Total assets	$	248,509,936	$	231,109,708

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES:
Accounts payable	$	4,387,829	$	5,012,157
Advances from customers - related parties		17,055,922		4,426,751
Wages and benefits payable		788,451		1,484,852
Income taxes payable		330,095		-
Contractor deposits		258,403		183,395
Contractor payables		20,942,557		18,513,216
Other payables		1,248,953		1,151,551
Other payables - related parties		1,502,767		3,326,110
Total current liabilities		46,514,977		34,098,032

NON-CURRENT LIABILITIES
Deferred income		11,283,364		11,236,501
Total non current liabilities		11,283,364		11,236,501

Total liabilities		57,798,341		45,334,533

EQUITY:
Shareholders' equity of the Company:
Common stock, $0.001 par value, 250,000,000 shares authorized,
71,333,586 issued and outstanding, respectively		71,334		71,334
Paid-in-capital		18,194,133		18,042,189
Statutory reserves		16,465,144		13,217,217
Retained earnings		126,769,661		126,370,263
Accumulated other comprehensive income		18,880,529		18,262,123
Total shareholders' equity of the Company		180,380,801		175,963,126
Noncontrolling interest		10,330,794		9,812,049
Total equity		190,711,595		185,775,175
Total liabilities and equity	$	248,509,936	$	231,109,708

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2010 AND 2009 (UNAUDITED)

	Six months ended June 30,
	2010			2009
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	4,111,465		$	19,315,168
Adjustments to reconcile net income to cash
provided by (used in) operating activities:
Bad debt expense		(116,962	)		(196,863	)
Depreciation		814,376			1,112,849
Amortization		167,147			194,380
Interest expense		-			2,710
Gain on sale of assets		(15,085	)		(15,717	)
Rental expense borne by a related party		163,532			163,331
(Increase) decrease in assets:
Accounts receivable, trade - related parties		6,725,384			(5,532,449	)
Other receivables		(1,349,264	)		10,743
Other receivables - related parties		213,304			(992,241	)
Inventories		(421,815	)		3,355,993
Employee advances		(121,454	)		(80,805	)
Prepaid expense		307,795			(435,576	)
Increase (decrease) in liabilities:
Accounts payable		(662,699	)		(1,579,065	)
Advances from customers - related parties		12,562,625			(219,470	)
Wages and benefits payable		(699,884	)		(703,898	)
Other taxes payable		615,431			8,920
Other payables		94,272			(395,970	)
Other payables - related parties		191,991			(202,847	)
Net cash provided by operating activities		22,580,159			13,809,193

CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in Life Resources		6,000,000			-
Collections from loans to local government		-			105,193
Proceeds from disposal of a subsidiary		700,000			-
Construction deposits		(2,678,074	)		(3,846,961	)
Contractor deposits		73,959			158,551
Addition to construction in progress		(18,790,772	)		(15,954,182	)
Equipment deposits		(6,133,065	)		-
Proceeds from sales of properties		2,621,558			17,039
Purchase of equipment and automobiles		(578,794	)		(921,388	)
Net cash used in investing activities		(18,785,188	)		(20,441,748	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Loan from (repayment to) related parties		-			(3,945,510	)
Net cash used in financing activities		-			(3,945,510	)

EFFECT OF EXCHANGE RATE CHANGES ON CASH		17,473			64,084

NET INCREASE (DECREASE) IN CASH		3,812,444			(10,513,981	)

CASH, beginning of period		1,848,328			44,854,511


CASH, end of period	$	5,660,772		$	34,340,530

Supplemental disclosures of cash flow information
Cash paid during the period for:
Interest	$	-		$	105,817
Income taxes	$	913,722		$	667,347

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

REVENUE BY REGION

	Three months ended
	June 30,

	2010		2009		Change

China	$	4,415,082	$	9,669,603		-54.3	%
International	$	3,752,767	$	10,881,433		-65.5	%
Total	$	8,167,849	$	20,551,036		-60.3	%

	Six months ended
	June 30,

	2010		2009		Change

China	$	11,198,355	$	12,412,223		-9.8	%
International	$	8,372,857	$	26,376,358		-68.3	%
Total	$	19,571,212	$	38,788,581		-49.5	%

TIENS BIOTECH GROUP USA INC 8-K